As of April 2021, Medicare requires the use of the JA or JB modifier when billing for drugs that have one Healthcare Common Procedure Coding System Level II (J or Q) code but multiple routes of administration.
Cohort Study Reveals Patients Treated with Rituximab Have Poorer COVID-19 Outcomes
According to a recent cohort study, patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab therapy experience more severe COVID-19. Researchers also found an association between rituximab use and prolonged hospital stays.
Add-On Voclosporin Improves Outcomes in Lupus Nephritis
NEW YORK (Reuters Health)—Voclosporin (Lupkynis) in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids improves renal response rates compared with use of these agents alone in patients with in lupus nephritis, according to a company-funded study. “Lupus nephritis can be a devastating condition if not diagnosed and managed early. These data establish voclosporin as an…
New French Law Extends Benefits to Families of Healthcare Workers Who Contracted COVID-19 & Died During the Pandemic
According to the French newspaper, Le Monde, the French Assembly adopted the “mort pour le service de la République”—died in the service of the Republic—statute on May 27. President Emmanuel Macron says this new law is one way to support the families of personnel who die under exceptional circumstances, such as healthcare providers who died…
COVID-19 Hate Crimes Act Passed
On May 20, with overwhelming support from Congress, President Biden signed legislation that addresses hate crimes committed during the COVID-19 pandemic, with particular emphasis on the increase in violence against Asian Americans. The law makes reporting hate crimes easier by ensuring reporting resources are available online in multiple languages. It also authorizes grants to state…
COVID-19 Outcomes in Patients with Rheumatic Disease
In a study of patients with systemic autoimmune rheumatic diseases (ARDs) and matched comparators with COVID-19 but without systemic ARDs, D’Silva et al. found COVID-19 patients with systemic ARDs may be at a higher risk of hospitalization, ICU admission and more than matched comparators.
Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis
An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.
Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar
Fear of injection decreased when patients with RA switched from self-administering a treatment biosimilar to etanercept in a prefilled syringe to an injector pen, according to a small observational study.
Virtual Hill Day Drives 100+ Congressional Conversations on Step Therapy, Workforce Shortages
On May 20, ACR representatives held more than 100 video meetings with Congressional leaders about the need to reform step therapy and alleviate pediatric workforce shortages. You can still add your voice by asking your members of Congress to support the Safe Step Act and fund the Pediatric Subspecialty Loan Repayment Program.
Myositis Management: Clinical Trials Provide New Insights into Treatment Options
Advancements in the treatment of myositis are on their way, according to Hector Chenoy, PhD, FRCP, who outlined the latest clinical trials during the 2021 ACR State-of-the-Art Clinical Symposium.
- « Previous Page
- 1
- …
- 144
- 145
- 146
- 147
- 148
- …
- 814
- Next Page »